Ophthalmic gene therapy case description
A 21-year-old Hispanic female had poor vision from birth including nyctalopia, visual field constriction, reduced visual acuity and reduced color perception. She noticed slowly progressive functional decline. Although she completed high school, she had worsening navigation and was challenged to live and work independently due to her visual limitations.
Pre-operative visual acuity was 20/150 in both eyes. The patient exhibited typical diffuse retinal degeneration with relative macular sparing. Genetic testing revealed biallelic RPE65 variants causing retinal degeneration and indicating type 2 Leber congenital amaurosis. Based upon the presence of viable retinal cells and potential benefit from ophthalmic gene therapy, treatment was offered by subretinal injection for both eyes. Surgeries were performed two weeks apart. The macular OCT and ultra-wide field fundus images showed baseline pigmentary retinopathy and photoreceptor alterations relatively sparing the fovea.
- Leber Congenital Amaurosis, EyeWiki, American Academy of Ophthalmology (AAO), Accessed on October 19th 2022
- Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2- hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–60
In this interview, Michael G. Richie, MD offers his expert opinion on the Proveo 8 from Leica…Aug 30, 2021Read article